clinical trial · NCT05159752
A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum (XP)
Clinuvel Europe Limited·phase2·unknown·n = 6
Xeroderma PigmentosumAfamelanotide
brief summary
The CUV156 study will evaluate the safety of afamelanotide in XP-C patients, as well as the drug's ability to assist reparative processes following ultraviolet (UV) provoked DNA damage of the skin. It will assess whether SCENESSE® increases the amount of UV light needed to cause DNA damage of skin cells, as well as the extent of skin repair before and after treatment.
started
Oct 19, 2021
primary completion
Mar 1, 2024
completion
Oct 1, 2024
last updated
Jun 18, 2023
official title
A Proof of Concept, Phase IIa, Open Label Study to Evaluate the Safety and Efficacy of Subcutaneous Implants of Afamelanotide in Patients With Xeroderma Pigmentosum (XP)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol